Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oncopeptides AB (publ)
  6. News
  7. Summary
    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Invitation to presentation of the Q3 2021 results

11/19/2021 | 09:01am EST

STOCKHOLM - November 19, 2021 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the third quarter 2021 on November 24. Investors, financial analysts, and media are invited to participate in a webcast with a QnA session on the same day at 10:00 CET. The event will be hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation will be held in English.

The webcast will be streamed via this link which can also be found on the website:
www.oncopeptides.com.


Phone numbers for participants from:

SE: +46 8 505 583 53
UK: +44 333 300 92 61
US: +1 833 823 05 89


For more information, please contact:

Rolf Gulliksen, Global Head of Corporate Communications, Oncopeptides AB
E-mail: rolf.gulliksen@oncopeptides.com
Cell phone: + 46 70 262 96 28

Linda Holmström, Director of Investor Relations, Oncopeptides AB
E-mail: linda.holmstrom@oncopeptides.com  
Cell phone: +46 70 873 40 95
 

About Oncopeptides

Oncopeptides is a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from the PDC platform, Pepaxto® (INN melphalan flufenamide), also called melflufen was granted accelerated approval in the U.S., on February 26,2021 in combination with dexamethasone, for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Oncopeptides voluntarily withdrew the drug from the U.S. market on October 22, 2021, due to worse overall survival data in the phase 3 OCEAN study. The study was a post-approval requirement under the accelerated approval program. Oncopeptides is developing several new compounds based on the PDC platform. The Corporate Headquarters is based in Stockholm, Sweden. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information about the company is available on www.oncopeptides.com.

https://news.cision.com/oncopeptides-ab/r/invitation-to-presentation-of-the-q3-2021-results,c3457181

https://mb.cision.com/Main/15404/3457181/1498975.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ONCOPEPTIDES AB (PUBL)
01/13Oncopeptides phase 3 OCEAN study published in the Lancet Haematology
AQ
01/13Oncopeptides AB Announces Data from Phase 3 Ocean Study Published in the Lancet Haemato..
CI
01/05Oncopeptides announces year-end cash 2021
AQ
2021Multiple Myeloma Hub continues to provide the latest treatment and research updates in ..
AQ
2021Oncopeptides presents new melflufen data at the Annual American Society of Hematology M..
AQ
2021Oncopeptides publishes Q3 2021 report
AQ
2021Oncopeptides AB Reports Earnings Results for the Third Quarter and Nine Months Ended Se..
CI
2021ONCOPEPTIDES : Webcast - Presentation of the Q3 Interim Report 2021
PU
2021Invitation to presentation of the Q3 2021 results
AQ
2021Oncopeptides Jumps 39% as New CEO Takes Over
MT
More news
Financials
Sales 2021 156 M 17,1 M 17,1 M
Net income 2021 -1 302 M -143 M -143 M
Net cash 2021 187 M 20,5 M 20,5 M
P/E ratio 2021 -0,45x
Yield 2021 -
Capitalization 608 M 66,8 M 66,7 M
EV / Sales 2021 2,69x
EV / Sales 2022 65,2x
Nbr of Employees 321
Free-Float -
Chart ONCOPEPTIDES AB (PUBL)
Duration : Period :
Oncopeptides AB (publ) Technical Analysis Chart | ONCO | SE0009414576 | MarketScreener
Technical analysis trends ONCOPEPTIDES AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 8,07 SEK
Average target price 5,35 SEK
Spread / Average Target -33,7%
EPS Revisions
Managers and Directors
Stig Anders Jakob Lindberg Chief Executive & Scientific Officer
Annika Muskantor Chief Financial Officer
Per Wold-Olsen Chairman
Fredrik Lehmann Head-Research, Chemistry, Manufacturing & Control
Klaas Bakker Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ONCOPEPTIDES AB (PUBL)-3.93%67
GILEAD SCIENCES, INC.-4.88%86 640
REGENERON PHARMACEUTICALS-2.12%64 627
VERTEX PHARMACEUTICALS5.12%58 692
WUXI APPTEC CO., LTD.-5.55%51 406
BIONTECH SE-37.29%39 044